23rd American Pharma & Biotech Project, Program and Portfolio Conference

16–18 Oct 2024 | Boston, Massachusetts, United States

Intelligencia AI

Solution provider

www.intelligencia.ai/New York, United States
7 profile visits

About

Intelligencia uses Artificial Intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We therefore aim to bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster. Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers brings together and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning fueled predictions to enable critical decision making. We currently work with several of the largest global pharmaceutical companies and mid-size and smaller biotechnology companies. Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.

Social media

Health

Research & DevelopmentProject ManagementClinical OperationsRisk ManagementAI ImplementationDecision MakingDrugsMedical DevicesBiotechBig PharmaSmall Pharma

Representatives

Marianna Esposito

Director, Business Development

Intelligencia AI

Hosted Sessions (1)

Wednesday, 16 October 2024

13:30 - 14:00

RESERVED PRESENTATION: Level-up and de-risk your portfolio strategy with AI

Format:In-personLocation:Beacon Hill Ballroom
  • Assessing Portfolio Risk